The no-observed-adverse-effect level refers to the highest dose tested in a nonclinical safety study at which no adverse finding was identified. The internationally used abbreviation is NOAEL. For planning a first administration in humans, this value provides a toxicological reference point, but it neither replaces the assessment of pharmacological activity nor the consideration of the exposure actually achieved.
Determination in nonclinical safety studies
A NOAEL is not derived by a simple calculation. It is derived from the finding profile of a suitable animal study after dose, duration, route of administration, clinical chemistry, pathology, and potential recovery have been assessed together. What matters is that the observed changes are classified as non-adverse; a biological effect may therefore be present without automatically excluding the NOAEL.
ICH guideline M3(R2) describes the NOAEL from nonclinical safety studies in the most appropriate animal species as key information for estimating the first dose in humans. For healthy volunteers, the EMA generally requires determination of the NOAEL and focuses on exposure in the most relevant species. This places concentration in the organism more clearly in the foreground than an isolated comparison of milligram values.
Role in the first dose in humans
In a first-in-human study, the animal exposure achieved at the NOAEL is related to an expected human exposure. This translation incorporates pharmacokinetic, toxicokinetic, and pharmacodynamic data. The protocol must justify the starting dose, the planned escalation steps, and the maximum exposure; insights from cohorts already treated can change further escalation.
However, the NOAEL is not necessarily the sole starting point. Where translatability is unclear, biological activity is high, or the target mechanism is particularly potent, MABEL, the pharmacologically active dose, and additional safety considerations may shape the outcome more strongly. Safety factors are not selected as a blanket approach; they are aligned with novelty, the dose–response curve, the relevance of the animal model, and the ability to monitor potential target-organ effects.
Distinction from the maximum tolerated dose
The no-observed-adverse-effect level is neither a dose with no effect at all nor a limit dose at which toxicity would just still be acceptable. It explicitly describes the absence of adverse effects in a nonclinical study. A signal at the intended target molecule, a reversible adaptation, or an expected pharmacological response must therefore be assessed scientifically rather than automatically being treated as an adverse effect.
The NOAEL is fundamentally different from the maximum tolerated dose. The maximum tolerated dose lies at the threshold of unacceptable burden and may include toxic findings; the NOAEL lies below it. In oncology, ICH S9 may provide for clinical dose finding up to dose-limiting toxicity or the maximum tolerated dose without a NOAEL necessarily having to underpin the clinical programme. The existing entry maximum-tolerated-dose therefore addresses a different dose concept.
Classifying a finding as adverse requires expert assessment in the context of the species studied. This includes the type of finding, severity, dose dependence, time course, and possible reversibility after dosing ends. A statistically notable value is not automatically adverse; conversely, a single pathological finding may be pivotal for the safety assessment despite limited frequency. This classification determines which dose level can be supported as the NOAEL.
For biopharmaceuticals, the interpretability additionally depends on whether the animal species is pharmacologically relevant. A NOAEL from a model without appropriate target binding cannot provide a robust safety threshold for humans. The exposure margin should therefore always be considered together with the species rationale, bioanalysis, and potential immunogenicity.
Relevance for clinical trials
In day-to-day study work, the NOAEL links the nonclinical final report with the dose rationale in the protocol and the Investigator’s Brochure. Teams must be able to understand which species was selected, at what exposure no adverse finding occurred, and what uncertainties remain in the extrapolation. Particularly during dose escalations, these linkages must be updated alongside the cohorts’ current safety, PK, and PD data.
Full-service CROs such as Mediconomics support the translation of nonclinical findings into a robust FIH dose strategy by coordinating toxicology tables, exposure comparisons, and stopping rules for the protocol. Regulatory Affairs, Medical Writing, and the clinical project team can then document the starting-dose rationale, the escalation logic, and the reporting pathways for observed risks consistently.
Frequently Asked Questions (FAQ)
Is the NOAEL always the highest administered dose?
Not necessarily. The highest tested level may already produce adverse findings. The NOAEL is then the highest lower dose level with no adverse effect identified.
Why is a NOAEL alone not sufficient for the starting dose?
The starting dose must also take into account potency, exposure prediction, differences between animals and humans, and the compound’s risk profile.
Does the NOAEL also apply to medicines for advanced cancers?
ICH S9 does not consider NOAEL and NOEL studies mandatory to support the clinical use of such oncology drugs; in this setting, clinical safety assessment carries particular weight.
Regulatory References
- ICH M3(R2), Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals – describes the NOAEL as the central nonclinical information for the first dose.
- EMA, Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials – places the NOAEL within starting-dose and exposure assessment.
- ICH S9, Nonclinical Evaluation for Anticancer Pharmaceuticals – explains the specific oncology context without a mandatory NOAEL requirement.